Bax­ter con­tin­ues on-shoring push with $50M In­di­ana ex­pan­sion

It’s been a ban­ner year for the once hum­drum busi­ness of man­u­fac­tur­ing drugs, par­tic­u­lar­ly vac­cines. Bil­lions have been spent ramp­ing up fa­cil­i­ties for Covid-19 jabs, while in­di­vid­ual CD­MOs have ex­pand­ed their fa­cil­i­ties, ap­par­ent­ly an­tic­i­pat­ing de­mand or re­spond­ing to a gov­ern­ment-led push to on­shore drug man­u­fac­tur­ing.

Now Bax­ter Bio­phar­ma So­lu­tions, the CD­MO wing of the many-armed health­care gi­ant Bax­ter, is get­ting in on the game. On Tues­day, they an­nounced plans to spend $50 mil­lion to ex­pand their flag­ship, 600,000 square-foot fa­cil­i­ty in Bloom­ing­ton, IN.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.